SAPRA™-applied Subthreshold Diode Microsecond Pulse (SDM™) Vision Protection Therapy™ is the future of vision loss for chronic progressive neurodegenerations of the eye including age-related macular degeneration, diabetic retinopathy, central serous chorioretinopathy, glaucoma, inherited retinopathies, and other macular disorders.
SDM™ Vision Protection Therapy™ is proven, highly effective, infinitely repeatable, and without any adverse treatment effects in decades of clinical application and laboratory study. SAPRA™ optimizes the SDM™ Vision Protection Therapy™ patient experience while eliminating the risk of surgeon error to make treatment of relentlessly progressive retinal disorders a reality for the first time.
SAPRA has not yet been evaluated and approved by the U.S. FDA or regulators for other geographies for commercial sales.
SAPRA™ is the first device designed perform modern retinal laser therapy, epitomized by SDM™ Vision Protection Therapy™
Treatment is non-invasive and safe; Locked parameters and built-in redundancies to further eliminate risk of harm from incorrect use
Simple & intuitive GUI and industrial design eliminates non-core elements of traditional lasers enabling providers to treat using SAPRA™ after only minutes of training by using a simple point-and-shoot approach to treatment application, akin to taking a cell phone photo
SAPRA™ is designed to maximize patient comfort. Non-contact optics eliminate the need for corneal contact lenses, eye drops or dilation. Treatment takes only seconds. Human factors engineering enhances patient accessibility and comfort, fostering compliance with the Vision Protection Therapy™ treatment program of regular periodic SDM™ designed to maintain the benefits of treatment initially and over a period of time.
Hormesis is one of the most important emerging sciences in medicine and the key to preventing aging and chronic disease. Retinal Thermal Hormesis ("RhyTHm") describes the way SAPRA™-applied SDM™ Vision Protection Therapy™ activates this powerful universal biologic process of cellular restoration and rejuvenation to reverse cellular aging, stop degeneration, and decrease chronic inflammation.
Targeted drug therapy seeks to overcome biologic complexity. Because of this complexity, it is seldom safe and effective even for a narrow range of applications. SAPRA™-applied SDM™ Vision Protection Therapy™ instead leverages biologic complexity via adaptive thermal hormesis to produce a physiologic "reset", normalizing retinal function. SDM™ Vision Protection Therapy™ is thus universally and robustly both safe and effective over a wide range of applications.
Age-Related Macular Degeneration Studies
Diabetic Macular Edema
Macular Edema
Open-Angle Glaucoma
Central Serous Chorioretinopathy
Macular Edema after Retinal Vein Occlusions
Proliferative Diabetic Retinopathy Studies
Inherited Retinal Degenerations
SAPRA™ has not yet been evaluated and approved by the U.S. FDA or regulators for other geographies for commercial sales
.png)
.png)